High-potency cannabis fuels state debates over psychosis and addiction risks

High-potency cannabis is fueling state debates over psychosis and addiction risks. The article notes a shift in legal-market potency, with many products now containing 15%–20% THC and concentrates such as waxes and oils exceeding 80%, far above older single-digit levels. Public health data show about 15% of Americans aged 12 and older used marijuana in the past month in 2024, and roughly three in ten cannabis users meet criteria for cannabis use disorder, according to federal statistics. In response, lawmakers in several states moved this year to impose potency caps or restrict high-THC products, while others paused or resisted measures amid industry opposition and research uncertainty. Dr. Alta DeRoo of the Hazelden Betty Ford Foundation cautions that changes in federal classification may not, by itself, reduce harm. Public-health researchers warn that public perceptions have not kept pace with potent products, complicating policy decisions. The article notes the federal move to reclassify medical marijuana as less restrictive under the Controlled Substances Act, a change some fear could reinforce the notion that cannabis is harmless. The debate spans youth protection, medical access, and industry interests, with advocates urging evidence-based limits and opponents warning of unintended consequences for patients and markets. The outcome will influence how other states calibrate potency caps and how policymakers approach legalization in the longer term.